UBS analyst David Dai lowered the firm’s price target on Cullinan Therapeutics (CGEM) to $24 from $30 and keeps a Buy rating on the shares. Cullinan’s key program CLN978 is on track for a data readout in the fourth quarter, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Cullinan Therapeutics Reports Q1 2025 Financial Results
- Promising Pipeline and Strategic Initiatives Drive Buy Rating for Cullinan Management
- Cullinan Management’s Long-Term Growth Potential: Buy Rating Despite Setbacks
- Cullinan Management’s Strategic Advancements and Financial Stability Justify Buy Rating
- Cullinan Therapeutics reports Q1 EPS (74c), consensus (81c)